Physician profile
Fred E Petrunak
NPI 1700844024
$1,558.53
in general payments reported to CMS, 2019-2025
18 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $212 · 2021: $175 · 2022: $249 · 2023: $242 · 2024: $312 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.24 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $271.57 | 2022-2025 | Miebo, Infuse, Xiidra |
| Alcon Vision LLC | $175.46 | 2019-2025 | Total30, Eysuvis |
| Coopervision INC. | $174.45 | 2020-2023 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $160.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $143.16 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $118.58 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $109.06 | 2019-2021 | |
| Topcon Healthcare, INC. | $83.29 | 2024 | |
| Kala Pharmaceuticals, INC. | $48.12 | 2021 | |
| Dompe US, INC. | $47.84 | 2024-2025 | Oxervate |
| Sight Sciences, INC. | $40.52 | 2023 | Tearcare System |
| Oyster Point Pharma, INC. | $38.88 | 2022-2024 | Tyrvaya |
| Thea Pharma INC. | $33.25 | 2023-2024 | Iyuzeh |
| Lkc Technologies, INC. | $32.19 | 2025 | |
| Genzyme Corporation | $23.33 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $22.80 | 2024 | Xdemvy |
| Abbvie INC. | $19.36 | 2022 | |
| Maculogix, INC. | $15.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fred Petrunak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.